NVCTNuvectis Pharma, Inc.
$20.13+229% 1Y
$20.13
$5.6552 weeks$28.52
NVCT as reported
- Net income
- −$28M
Net income · +26% year on year · trailing twelve months to Q2 2026
- EPS
- −$1.31
EPS · +12% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$28M | +26% | Q2 2026 |
| EPS | −$1.31 | +12% | Q2 2026 |
| ROE | −187% | n/a | Q2 2026 |
| ROA | −97% | n/a | Q2 2026 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Nuvectis Pharma, Inc. (NVCT) · Net incomeNet incomeNuvectis Pharma, Inc. (NVCT)